Among other gastric cancer-associated genes, the epigenetic modifier KMT2B was also more frequently mutated in cancers with higher CDX2 expression (12.6% versus 3.2% in cancers with lower CDX2, Fisher’s exact test p = 0.03, Figure 1). This evidence concerns the gene CDX2 and cancer.